PTC Therapeutics, Inc. (PTCT)

SpringWorks Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1,773	806.78	937.82	698.8	538.59	380.77
Revenue Growth (YoY)	91.12%	-13.97%	34.20%	29.75%	41.45%	24.04%
Cost of Revenue	582.84	591.88	732.05	696.17	573.01	442.99
Gross Profit	1,190	214.9	205.77	2.63	-34.42	-62.22
Selling, General & Admin	308.6	300.91	332.54	326	285.77	244.46
Operating Expenses	321.61	361.65	555.18	442.55	340.52	281.36
Operating Income	868.31	-146.75	-349.4	-439.93	-374.94	-343.58
Interest Expense	-169.96	-170.39	-128.88	-90.87	-86.02	-56.35
Interest & Investment Income	6.31	-	-	-	-	-
Currency Exchange Gain (Loss)	-7.6	-	9	-31.3	-	-
Other Non Operating Income (Expenses)	101.06	98.12	2.81	-0.62	-45.19	51.63
EBT Excluding Unusual Items	798.11	-219.02	-466.48	-562.71	-506.15	-348.3
Merger & Restructuring Charges	-	-	-	-	-	-0.3
Gain (Loss) on Sale of Investments	8.49	11.73	-1.98	-17.29	-12.69	33.56
Asset Writedown	-168.08	-168	-217.8	-33.38	-	-54
Other Unusual Items	12.88	12.18	-9.86	25.9	0.5	-33.89
Pretax Income	651.41	-363.12	-696.11	-587.49	-518.34	-402.93
Income Tax Expense	56.56	0.18	-69.51	-28.47	5.56	35.23
Net Income	594.84	-363.3	-626.6	-559.02	-523.9	-438.16
Net Income to Common	594.84	-363.3	-626.6	-559.02	-523.9	-438.16
Shares Outstanding (Basic)	77	77	75	72	70	66
Shares Outstanding (Diluted)	79	77	75	72	70	66
Shares Change (YoY)	5.01%	2.68%	4.33%	1.79%	6.72%	12.17%
EPS (Basic)	7.70	-4.73	-8.37	-7.79	-7.43	-6.64
EPS (Diluted)	7.51	-4.73	-8.37	-7.79	-7.43	-6.64
Free Cash Flow	693.02	-114.19	-186.86	-388.67	-279.55	-211.91
Free Cash Flow Per Share	8.74	-1.49	-2.50	-5.42	-3.97	-3.21
Gross Margin	67.12%	26.64%	21.94%	0.38%	-6.39%	-16.34%
Operating Margin	48.98%	-18.19%	-37.26%	-62.95%	-69.62%	-90.23%
Profit Margin	33.55%	-45.03%	-66.81%	-80.00%	-97.27%	-115.07%
Free Cash Flow Margin	39.09%	-14.15%	-19.92%	-55.62%	-51.90%	-55.66%
EBITDA	895.8	-71.08	-112.81	-311.09	-310.81	-300.09
EBITDA Margin	50.53%	-8.81%	-12.03%	-44.52%	-57.71%	-78.81%
D&A For EBITDA	27.49	75.66	236.59	128.84	64.13	43.49
EBIT	868.31	-146.75	-349.4	-439.93	-374.94	-343.58
EBIT Margin	48.98%	-18.19%	-37.26%	-62.95%	-69.62%	-90.23%
Revenue as Reported	1,773	806.78	937.82	698.8	538.59	380.77

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q